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Summary
The expression of podoplanin, a small mucin-like protein, is upregulated in the invasive front of a number of human carci-
nomas. We have investigated podoplanin function in cultured human breast cancer cells, in a mouse model of pancreatic
b cell carcinogenesis, and in human cancer biopsies. Our results indicate that podoplanin promotes tumor cell invasion
in vitro and in vivo. Notably, the expression and subcellular localization of epithelialmarkers are unaltered, andmesenchymal
markers are not induced in invasive podoplanin-expressing tumor cells. Rather, podoplanin induces collective cell migration
by filopodia formation via the downregulation of the activities of small Rho family GTPases. In conclusion, podoplanin
induces an alternative pathway of tumor cell invasion in the absence of epithelial-mesenchymal transition (EMT).Introduction
A critical step in the development of a malignant tumor is charac-
terized by a gain in the tumor cells’ migratory and invasive capa-
bilities. In the past years, a number of molecular mechanisms
have been identified by which normal and transformed cells be-
come migratory and invasive during embryonic development
and during carcinogenesis. These processes include induction
of cellular migration and invasion by receptor tyrosine kinase-
mediated signal transduction pathways, by changes in cell adhe-
sion, and by the activation of small GTPases of the Rho family,
which in turn leads to the reorganization of the actin cytoskeleton
(reviewed by Cavallaro and Christofori, 2004; Grunert et al.,
2003; Sahai and Marshall, 2002; Thiery, 2002). Yet, the molecular
details of how tumor cells acquire these malignant properties are
still poorly understood.
Oncogenic events in tumor cells as well as growth factors se-
creted by tumor and stromal cells induce a multistep process
termed epithelial-mesenchymal transition (EMT; reviewed in
Grunert et al., 2003; Siegel and Massague, 2003; Thiery, 2002).
During EMT, cells progressively redistribute or downregulate their
apical and basolateral epithelial-specific proteins, such as E-CANCER CELL 9, 261–272, APRIL 2006 ª2006 ELSEVIER INC. DOI 10.1cadherin, catenins, and cytokeratins, and re-express mesenchy-
mal molecules, such as vimentin, fibronectin, and N-cadherin.
These changes lead to the abrogation of cell-cell contacts and
the gain of cell motility necessary for invasion. EMT of in vitro cul-
tured cells resembles the metastatic process observed inpatients,
although this hypothesis is still under debate (Grunert et al., 2003).
Previously, our laboratory has demonstrated that loss of E-
cadherin function is a rate-limiting step during the transition
from adenoma to carcinoma (Perl et al., 1998). Concomitant
with the loss of E-cadherin, a strong upregulation of N-cadherin
expression is observed. Such a cadherin switch has been previ-
ously described during the progression of various cancer types
and is thought to be necessary for tumor cells to gain invasive
properties (Cavallaro et al., 2002; Hsu et al., 1996). Migration
and invasion of tumor cells are also promoted by the loss of inter-
action of adherens junctions with the cytoskeleton, subsequent
changes in the activities of Rho family small GTPases (most
prominently Rac1, Cdc42, and RhoA), and the concomitant reor-
ganization of the actin cytoskeleton (Noren et al., 2000; Sahai
and Marshall, 2002).
Despite the major progress in the understanding of the molec-
ular processes underlying EMT and tumor progression, a numberS I G N I F I C A N C E
In most epithelial cancers, the expression of E-cadherin is lost during the transition from adenoma to carcinoma. Here, we report amo-
lecular pathway of tumor progression that does not involve the loss of E-cadherin function or epithelial-mesenchymal transition: podo-
planin, which is frequently upregulated in the invasive front of humancancers, induces tumor cellmigration and invasion in breast can-
cer cells in vitro and in a mouse model of tumorigenesis in vivo without dissolving E-cadherin-mediated junctional complexes.
Podoplanin induces the formation of filopodia by modulating the activities of Rho-family GTPases, which ultimately leads to collective
cell invasion, a phenotype often observed in human carcinoma. These results raise important questions about diagnosing malignant
disease and designing adequate antimetastatic therapies.016/j.ccr.2006.03.010 261
A R T I C L Eof questions still remain unresolved. For example, a significant
number of cancers, including certain subtypes of breast and
ovarian cancers, are by pathological criteria characterized as in-
vasive and malignant, yet they do not lose E-cadherin expres-
sion. Moreover, full EMT is rarely observed in biopsies from can-
cer patients.
Recently, podoplanin (PA2.26, T1a-2, aggrus), a small, 38 kDa
mucin-type transmembrane glycoprotein, has been implicated in
tumor progression. The expression of podoplanin is upregulated
in a number of different cancers, including squamous cell carci-
noma of the oral cavity, lung, and skin, granulosa cell tumors,
and mesothelioma (Kato et al., 2005; Kimura and Kimura, 2005;
Martin-Villar et al., 2005; Schacht et al., 2005). Podoplanin is ex-
pressed in human kidney podocytes and is homologous to T1a-2,
an antigen expressed on the apical surface of alveolar type I cells
(Rishi et al., 1995). Other podoplanin homologs include OTS-8,
RTI40, gp 38, canine gp 40, human gp 36, and murine PA 2.26
(Farr et al., 1992; Gonzalez and Dobbs, 1998; Martin-Villar
et al., 2005; Nose et al., 1990; Zimmer et al., 1997; Zimmer
et al., 1999). Since podoplanin is expressed on lymphatic endo-
thelium but not on blood vessel endothelium, it is also widely
used as a specific marker for lymphatic endothelial cells and lym-
phangiogenesis (Breiteneder-Geleff et al., 1999). Podoplanin-
deficient mice die at birth due to respiratory failure, exhibiting
a phenotype of dilated, malfunctioning lymphatic vessels and
lymphedema (Schacht et al., 2003). Yet, the physiological func-
tion of podoplanin is still unknown. Also, the functional contribu-
tion of podoplanin to tumor progression has remained elusive.
Early experiments addressing this issue have revealed that podo-
planin colocalizes with ezrin, an ERM-protein (ezrin-radixin-moe-
sin), at the cellular membrane, and that podoplanin promotes
relocalization of ezrin to filopodia-like structures and reduces
cell-cell adhesiveness (Martin-Villar et al., 2005). In this context,
it is important tonote thatezrin itself hasbeen regardedasa tumor
promoter, since its overexpression can enhance tumor progres-
sion in various cancer models (Hunter, 2004; McClatchey, 2003).
Here, we have investigated the functional role of podoplanin
during tumor progression in vitro and in vivo. To this end, we gen-
erated transgenic mouse lines expressing podoplanin under the
control of the rat insulin promoter in the b cells of islets of Lang-
erhans (Rip1Podo). We then crossed Rip1Podo mice into the
Rip1Tag2 transgenic mouse model of pancreatic b cell carcino-
genesis (Hanahan, 1985). In Rip1Tag2 transgenic mice, Simian
Virus 40 large and small T antigen are expressed under the con-
trol of the rat insulin promoter. These mice reproducibly develop
tumors in a multistage tumorigenesis pathway involving islet hy-
perplasia, the formation of new blood vessels (angiogenesis),
and, finally, b cell adenomas and carcinomas (Christofori et al.,
1994; Folkman et al., 1989; Perl et al., 1998). The impact of forced
expression of podoplanin on tumor progression in double trans-
genic Rip1Podo;Rip1Tag2 mice was then compared to single
transgenic Rip1Tag2 mice. In addition, we established MCF7
breast cancer cell lines that stably expressed podoplanin and
analyzed podoplanin-mediated changes in various cellular pa-
rameters, including cell migration and invasion. Finally, we
employed tumor biopsies from cancer patients to correlate
podoplanin expression with tumor invasion. Together, the results
from these in vivo and in vitro experiments indicate that podopla-
nin employs a novel molecular pathway of inducing collective
tumor cell invasion in the absence of profound changes in junc-
tional adhesion complexes or EMT.262Results
Generation of Rip1Podo transgenic mice
We have generated transgenic mice expressing murine podo-
planin specifically in the insulin-producing b cells of the pancre-
atic islets of Langerhans. A cDNA encoding murine podoplanin
was cloned between a rat insulin II promoter fragment and
a human growth hormone intron and polyadenylation signal,
thus targeting podoplanin expression to pancreatic b cells
(Hanahan, 1985). Six independent transgenic mouse lines were
established that exhibited stable transmission of the transgene
to their progeny. Rip1Podo transgenic mice were viable, normo-
glycemic, and fertile. Analysis of transgene expression was
examined at the RNA level by RT-PCR (data not shown) and by
immunofluorescent staining of histological sections of pancreata
of transgenic mice (Figure S1). Strong podoplanin expression
was detected in all islets of several Rip1Podo mouse lines, but
not in nontransgenic littermate controls. In the exocrine pan-
creas, the only detectable podoplanin protein could be attributed
to lymphatic vessels.
Histopathological analyses of both adult and newborn pan-
creas did not reveal any significant differences in islet morphol-
ogy between Rip1Podo mice and nontransgenic littermate
controls, although transgenic podoplanin expression could be
detected already in islets of newborn mice. Also, the presence
and distribution of cells producing insulin, glucagon, pancreatic
polypeptide, and somatostatin was unaltered regardless of the
age of the mice (data not shown). Moreover, the expression of
podoplanin affected neither blood vessel density and morphol-
ogy within the islets of Langerhans nor the morphology and
distribution of lymphatic vessels, which were exclusively found
in the exocrine pancreas in control and in Rip1Podo mice (data
not shown).
Podoplanin promotes invasion of b cell tumors
We next crossed Rip1Podo mice with Rip1Tag2 mice in order to
generate double-transgenic Rip1Podo;Rip1Tag2 mice. Both
single and double-transgenic mice were kept in a C57Bl/6 back-
ground. Single-transgenic Rip1Tag2 mice were used as experi-
mental controls to identify podoplanin-specific effects on tumor
progression in double-transgenic Rip1Podo;Rip1Tag2 mice.
Obvious physiological or pathological differences or changes
in life span were not detected between single-transgenic and
double-transgenic mice.
Mice were sacrificed between the age of 12 and 13 weeks,
a time point when Rip1Tag2 mice succumb to hypoglycemia.
Histological staging and grading was performed on paraffin
sections of pancreata from double-transgenic Rip1Podo;
Rip1Tag2 and from single-transgenic Rip1Tag2 mice on the ba-
sis of the 2001 WHO classification of rodent tumors (Mohr et al.,
2001). Islets and b cell tumors were staged into normal islets,
hyperplastic islets, adenoma (noninvasive tumor), or carcinoma
(invasive tumor) with 3 grades: grade 1, invasive tumors with
the invading front comprising less than 20% of the entire tumor
periphery; grade 2, carcinoma with more than 20%; grade 3, car-
cinoma with high-grade invasion, nuclear atypia, and anaplasia.
Detailed analysis of pancreata from 18 double-transgenic and 13
single-transgenic mice revealed that podoplanin-expressing
mice exhibited a higher incidence of carcinomas than single-
transgenic controls (Figure 1A). In particular, the number of grade
2 carcinomas was significantly higher in Rip1Podo;Rip1Tag2CANCER CELL APRIL 2006
A R T I C L Emice (Figure 1B). Lymph node and distant organ metastasis were
not detected in either single-transgenic or double-transgenic
mice.
Expression of podoplanin during Rip1Tag2 tumorigenesis af-
fected neither tumor incidences nor tumor volumes. Moreover,
the rates of tumor cell apoptosis and tumor cell proliferation,
as assessed by TUNEL and BrdU incorporation assays, respec-
tively, were not significantly altered by podoplanin (Figures S2A
and S2B). Since podoplanin has been reported to play a role in
the development of lymphatic vessels (Schacht et al., 2003),
we also examined the morphology and density of blood and lym-
phatic vessels in Rip1Podo;Rip1Tag2 double-transgenic mice
by immunohistochemical staining with antibodies against
CD31 and LYVE-1, respectively (Figures S2C–S2F). No apparent
difference in blood and lymphatic vessel morphology could be
detected, and quantitation of vessel densities did not reveal
any significant impact of podoplanin expression on blood vessel
angiogenesis and lymphangiogenesis during tumor progression
(data not shown). From these analyses, we conclude that
Figure 1. Accelerated tumor progression in Rip1Podo;Rip1Tag2 double-
transgenic mice
A: Distribution of adenomas and carcinomas in Rip1Podo;Rip1Tag2 double-
transgenic and Rip1Tag2 single-transgenic mice. The incidence of adeno-
mas is reduced from 48% in Rip1Tag2 to 33% in Rip1Podo;Rip1Tag2 mice.
Conversely, the incidence of carcinomas is increased in Rip1Podo;Rip1Tag2
mice (*p = 0.04, Fisher’s exact test). Data are shown as mean 6 SEM.
B: Grading of tumor stages in Rip1Podo;Rip1Tag2 double-transgenic and
Rip1Tag2 single-transgenic mice. Carcinomas were graded according to
the size of the invading front and the degree of nuclear atypia (see text).
Invasiveness of tumors in double-transgenic Rip1Podo;Rip1Tag2 mice was
significantly enhanced (*p = 0.005, chi-square test). Data are shown as
mean 6 SEM.CANCER CELL APRIL 2006podoplanin promotes tumor invasiveness in vivo by conferring
migratory and invasive properties to tumor cells without affecting
other tumor growth parameters.
Podoplanin bypasses EMT during Rip1Tag2 tumor
progression
We have previously demonstrated that the loss of E-cadherin ex-
pression is a rate-limiting step in the transition from adenoma to
carcinoma during Rip1Tag2 tumorigenesis (Perl et al., 1998). To
assess whether podoplanin modulates the transition from ade-
noma to carcinoma by affecting the epithelial character of tumor
cells, E-cadherin expression in tumors from Rip1Tag2 mice and
Rip1Podo;Rip1Tag2 mice was analyzed by immunofluores-
cence staining with antibodies against E-cadherin. As expected,
in Rip1Tag2 control mice, E-cadherin staining was absent in in-
vasive tumors (Figure 2A). In contrast, in podoplanin-expressing
tumors, strong E-cadherin staining could be observed at the
membranes of most tumor cells (Figure 2B). Double staining for
the expression of E-cadherin and podoplanin revealed a strong
colocalization of E-cadherin and podoplanin at cell-cell junc-
tions, even of invasive tumor cells (Figures 2C and 2D). To verify
whether E-cadherin is present at the tumor rim and in the invad-
ing front, the expression of E-cadherin was also analyzed by
immunohistochemical staining on frozen sections. In tumors
from Rip1Tag2 control mice, E-cadherin was undetectable in
invasive tumor cells (Figure 2E). In contrast, E-cadherin was still
present inpodoplanin-expressing tumor cells in the invading front
of carcinomas (Figure 2F). The majority of carcinomas in the
podoplanin overexpressing mice were positive for E-cadherin,
whereas most carcinomas in control mice had lost E-cadherin
expression (Figure 2G). This surprising observation suggests
that in the presence of podoplanin the induction of tumor inva-
sion is not dependent on the loss of E-cadherin function. Yet,
the fact that approximately 14% of the podoplanin-expressing
carcinomas are negative for E-cadherin expression indicates
that podoplanin does not necessarily prevent the loss of E-
cadherin expression in invasive tumor cells.
We next examined whether the expression of other epithelial
markers, such as the cytoplasmic adherens junction proteins
b catenin and p120 catenin, was maintained together with
E-cadherin at the cell membrane of podoplanin-expressing
b tumor cells. No membrane staining for b catenin and p120
catenin was detectable in carcinomas of Rip1Tag2 mice, except
for vascular cells within the tumor area (Figures S3A and S3C). In
contrast, in the invasive fronts of podoplanin-expressing tumors,
together with the continuing expression of E-cadherin, a strong
membrane staining for both b catenin and p120 catenin could
be detected (Figures S3B and S3D). Analysis of the expression
of the tight junction protein ZO-1 revealed comparable results
(Figure S4).
Next, we determined whether a cadherin switch, i.e., the
switch from E-cadherin to N-cadherin expression, occurred in
podoplanin-expressing tumors. In the carcinomas of Rip1Tag2
control mice, expression of E-cadherin was lost and the expres-
sion of N-cadherin was strongly upregulated (Figures 3A and
3C). In contrast, in podoplanin-expressing tumors, only a very
weak staining for N-cadherin was detectable, while E-cadherin
expression remained present (Figures 3B and 3D). Apparently,
a switch in cadherin expression is not required for the
development of invasive carcinomas in double-transgenic
Rip1Podo;Rip1Tag2 mice. Instead, E-cadherin, together with263
A R T I C L EFigure 2. Podoplanin induces tumor invasiveness without loss of E-cadherin
expression
A–D: Pancreatic sections from Rip1Tag2 (A) and Rip1Podo;Rip1Tag2 (B, C,
and D) were stained by immunofluorescence with antibodies against
E-cadherin (green) and podoplanin (red) as indicated. Note that the invasive
b cell carcinoma of a single-transgenic Rip1Tag2 mouse has lost E-cadherin
expression (A), whereas podoplanin-expressing tumor cells, despite their ap-
parent invasion into surrounding tissue, maintain the expression of E-cad-
herin (B and C). Podoplanin and E-cadherin colocalize at cell membranes
in these cells (D). Blue staining, DAPI (nuclei).
E and F: Immunohistochemical visualization of E-cadherin expression. E-cad-
herin expression (brown) is lost in an invasive carcinoma of a Rip1Tag2
mouse, while it is present in the exocrine pancreatic tissue (E). In an invasive
carcinoma of a Rip1Podo;Rip1Tag2 mouse, E-cadherin expression (brown) is
maintained even in the invading front of the tumor (F).
G: Quantitation of E-cadherin expression in classified carcinomas of
Rip1Tag2 and Rip1Podo;Rip1Tag2 mice. While only 7% of carcinomas in
Rip1Tag2 mice showed E-cadherin expression, approximately 86% of the
carcinomas of double-transgenic Rip1Podo;Rip1Tag2 mice maintained
expression of E-cadherin (*p = 0.0009, Fisher’s exact test). Data are shown
as mean 6 SEM. Ex, exocrine tissue; Tu, tumor tissue. Scale bar = 100 mm.264other adherens and tight junction markers, remains at the mem-
branes of invasive carcinoma cells. These results raise the in-
triguing possibility that podoplanin is able to induce tumor cell in-
vasion without dissolving epithelial adherens and tight junctions.
Podoplanin relocalizes ERM proteins and rearranges
the actin cytoskeleton
Recently, it has been demonstrated that ezrin colocalizes with
podoplanin at the cellular membrane in filopodia-like structures
(Martin-Villar et al., 2005). Furthermore, ezrin is upregulated in
invasive esophageal cancer cells (Shen et al., 2003) and may
play a critical role in tumor metastasis (Hunter, 2004). We there-
fore investigated the distribution of ezrin both in tumors of podo-
planin-transgenic mice and in control mice. In invasive tumors of
Rip1Tag2 mice, ezrin was localized to the subcortical compart-
ment of the cells, beneath the cellular membrane in the periphery
of the cytoplasm (Figure 4A). In tumors of podoplanin-expressing
mice, ezrin was redistributed to the edges of invasive tumor
cells (Figure 4B). Double staining for ezrin and podoplanin con-
firmed the relocalization of ezrin and demonstrated a colocaliza-
tion of podoplanin with ezrin in filopodia-like membrane foci
(Figure 4C). Staining for moesin, another ERM protein, showed
a comparable pattern (data not shown). Thus, podoplanin over-
expression exerts a profound effect on the cellular distribution of
ERM proteins, and ERM proteins appear to colocalize with podo-
planin in filopodia-like structures at the cell membrane of inva-
sive tumor cells.
Figure 3. Podoplanin-mediated tumor cell invasion does not involve a cad-
herin switch
Immunofluorescence staining for N-cadherin (red) (A and B) and double
staining for N-cadherin (red) and E-cadherin (green) (C and D) on pancre-
atic sections from Rip1Tag2 (A and C) and Rip1Podo;Rip1Tag2 (B and D)
mice. Note that in carcinomas of Rip1Tag2 single-transgenic mice, con-
comitant with the loss of E-cadherin expression, the expression of N-cad-
herin is upregulated. In contrast, in tumors of Rip1Podo;Rip1Tag2 double-
transgenic mice, E-cadherin expression is maintained and N-cadherin is
not upregulated. Blue staining, DAPI (nuclei); Ex, exocrine tissue; Tu, tumor tis-
sue. Scale bar = 100 mm.CANCER CELL APRIL 2006
A R T I C L EBoth ZO-1 and ERM proteins are known to bind and modulate
the actin cytoskeleton (McClatchey, 2003; Smalley et al., 2005).
To investigate the consequences of podoplanin overexpression
on the actin cytoskeleton, we performed fluorescent phalloidin
staining on histological sections of tumors from Rip1Tag2 and
Rip1Podo;Rip1Tag2 mice. In control mice, staining of actin fila-
ments appeared in the subcortical compartment of the cells
(Figure 4D). In podoplanin-expressing tumor cells, actin filament
staining was generally reduced, yet a significant subset re-
mained in focal membrane areas, which resemble filopodia
(Figure 4E). Proper membrane localization of E-cadherin indi-
cated that the relocalization of actin filaments was not caused
by damage to membrane structures in podoplanin-expressing
tumor cells (Figure 4F). Taken together, actin filament localiza-
tion is strongly affected by the presence of podoplanin: subcor-
tical actin filaments are markedly reduced in podoplanin-
expressing tumor cells and are relocalized to filopodia-like foci
at the plasma membrane.
Podoplanin induces filopodia formation, cell migration,
invasion, and spreading in vitro
To investigate whether the upregulated expression of podopla-
nin affected E-cadherin expression as well as cell morphology
and function in cultured tumor cells in vitro, MCF7 breast carci-
noma cells were stably transfected with a podoplanin expression
Figure 4. Ezrin and actin filaments are relocalized by podoplanin
A–C: Immunofluorescence staining for ezrin (green) and podoplanin (red)
on pancreatic sections of Rip1Tag2 (A) and Rip1Podo;Rip1Tag2 (B and C)
mice, as indicated. Note that ezrin is distributed cortically at the cell mem-
brane throughout the tumor of a Rip1Tag2 mouse (A), whereas its presence
is more irregular with significant localization to focal membrane regions in
tumor cells of Rip1Podo;Rip1Tag2 mice (B). Double staining of pancreatic
sections from Rip1Podo;Rip1Tag2 mice reveals that ezrin (green) and podo-
planin (red) colocalize (yellow) at filopodia-like structures at the plasma
membrane of podoplanin-expressing b tumor cells, indicated by arrow
heads (C).
D–F: Fluorescent phalloidin staining for actin (D and E) and E-cadherin (F) on
pancreatic sections from Rip1Tag2 (D) and Rip1Podo;Rip1Tag2 (E and F)
mice, as indicated. Note the regular subcortical distribution of actin in
b tumor cells of Rip1Tag2 mice, yet an irregular pattern with foci of actin
accumulation in tumor cells of Rip1Podo;Rip1Tag2 mice. Staining for E-cad-
herin on adjacent histological sections demonstrates intact cell membranes
in the tumor cells of Rip1Podo;Rip1Tag2 mice. Blue staining, DAPI (nuclei).
Scale bar = 100 mm.
Inserts in A–F represent higher magnifications of single cells.CANCER CELL APRIL 2006construct or with empty vector as control. MCF7 cells are known
to express high levels of E-cadherin and to exhibit epithelial mor-
phology. Four control and four podoplanin-transfected clonal
cell lines were selected, and the expression of podoplanin was
verified by immunoblotting and immunofluorescence analysis
(Figure S5A and Figures 5B, 5D, and 5F, respectively). As ex-
pected, MCF7-control cells formed epithelial layers with pro-
nounced E-cadherin-mediated adherens junctions. No staining
for podoplanin was detectable (Figure 5A). Expression of podo-
planin in MCF7-podoplanin cells caused a dramatic change in
cellular shape and migratory behavior with the formation of
many filopodia-like structures (Figure 5B). Podoplanin was found
to be evenly distributed in all plasma membranes. Similar to b tu-
mor cells in Rip1Podo;Rip1Tag2 mice, podoplanin expression
did not result in a loss of E-cadherin function, yet colocalization
between E-cadherin and podoplanin was restricted to cell-cell
junctions where no filopodia-like protrusions were observed
(Figure 5B). No upregulation of EMT markers such as N-cadherin
or vimentin could be observed in podoplanin-transfected MCF7
cells (Figure S5B). To demonstrate that MCF7 cells were actually
able to undergo EMT, we ablated E-cadherin expression in these
cells by transfection of a specific antisense shRNA vector
(pSuperRetro Ecad). Indeed, upon marked reduction of E-
cadherin expression, MCF7 cells upregulated the expression of
N-cadherin and vimentin, an indication for EMT (Figure S5B).
This finding underlines the observation that podoplanin does not
induce a cadherin switch or EMT.
Double staining for podoplanin and ezrin in podoplanin-
expressing MCF7 cells confirmed the colocalization of podopla-
nin and ezrin at the cell membrane of microspikes and filopodia
(Figures 5C and 5D). Double staining for podoplanin and phalloi-
din/actin revealed a dramatic reduction in actin stress fibers in
podoplanin-transfected cells, with an evident relocalization of
actin to filopodia (Figures 5E, 5F, and 5G). To investigate a direct
physical interaction between podoplanin, E-cadherin, ezrin, and
actin, we performed immunoprecipitation experiments with
specific antibodies against podoplanin. However, none of the
aforementioned molecules coprecipitated with podoplanin
(data not shown). Yet, these experiments revealed that the phos-
porylated form of ezrin was much more abundant in podoplanin-
transfected cells (Figure 5I), suggesting that podoplanin indi-
rectly affects ezrin function and with it the actin cytoskeleton.
Cell spreading has been shown to be mediated by filopodia
formation (Price et al., 1998). To assess whether the filopodia
that formed upon the expression of podoplanin were functional,
we compared control and podoplanin-transfected cells for their
ability to spread on culture dishes precoated with fibronectin.
Cell spreading was significantly accelerated in podoplanin-
transfected cells (Figures 6A and 6B), which could be repressed
by neutralizing antibodies against b1 integrin (data not shown).
Next, we performed in vitro scratch wounding assays on con-
fluent monolayers of MCF7 cells (Figure S6). With podoplanin-
transfected cells, a broad migrating front was visible in the gap
after 8 hr, and after 24 hr the gap had closed, whereas with
MCF7-control cells, only a few single migrating cells were de-
tectable after 8 hr and the gap had not closed after 24 hr. Rates
of cell proliferation were not different between podoplanin-trans-
fected and control cells, excluding any proliferation effects on
cell migration (Figure S5C). To determine whether the podopla-
nin-mediated increase in cell migration was accompanied by
cell polarization, the cells in the scratch wounding assays were265
A R T I C L EFigure 5. Podoplanin induces a migratory phe-
notype in MCF7 cells
A: Double staining against podoplanin and
E-cadherin in MCF7 control cells does not reveal
any podoplanin (red) expression, yet demon-
strates high levels of E-cadherin (green) in cell-
cell junctions.
B: Expression of podoplanin (red) in MCF7-podo-
planin cells does not abrogate E-cadherin
(green) expression at cell junctions.
C:Double staining for podoplanin (red) and ezrin
(green) reveals a regular, subcortical distribution
of ezrin (green) in MCF7-control cells.
D: In contrast, a strong colocalization of both
molecules is evident in filopodia-like structures
of podoplanin-expressing MCF7 cells (yellow).
E and F: Immunofluorescence staining of podo-
planin (red) and actin/phalloidin (green) reveals
many stress fibers in MCF7 control cells (E),
whereas stress fibers are dissolved and actin fila-
ments are redistributed to filopodia-like structures
in podoplanin-transfected cells (yellow) (F).
G: The number of filopodia (defined as F actin
positive membrane protrusion of >5 mm length)
is significantly increased in podoplanin-trans-
fected MCF7 cells as compared to control cells
(*p < 0.0001, two-sided t test).
H: Conversely, the number of stress fibers is dra-
matically reduced in podoplanin-transfected
cells (*p < 0.0001, two-sided t test). Data are
shown as mean 6 SEM.
I: Immunoblotting analysis of ezrin phosphoryla-
tion. The level of phospho-ezrin (but not total
ezrin) is increased in podoplanin-transfected
cells as compared to control MCF7 cells. Scale
bar = 20 mm.stained with antibodies against the specific cis-Golgi marker
p115 (Gadea et al., 2002). While 25% of the control cells ex-
hibited a polarized orientation of the Golgi apparatus, 42% of
podoplanin-expressing cells migrated in a polarized manner
(p < 0.016, chi-square test).
The effect of podoplanin expression on cell migration and inva-
sion was quantified by two-chamber migration and invasion
assays, where podoplanin-expressing and control MCF7 cells
were seeded in the upper chamber of transwell inserts and
migration of cells along a serum gradient through a membrane
was observed. In the invasion assay, transwell membranes
were additionally coated with a layer of polymerized matrigel.
These experiments revealed that migration of podoplanin-trans-
fected cells was significantly higher as compared to control cells
(Figure 6C), and that the invasion rate was even more pro-
nounced in podoplanin-expressing cells as compared to control
cells (Figure 6D).
Since the invasive behavior of tumor cells and in particular of
cells of the invading front is known to be influenced by growth
factors derived from the tumor stroma, we set out to investigate
whether podoplanin expression can be induced by stromal fac-
tors. MCF7 cells were stimulated for different time periods with
FGF2, EGF, TGFb, IGF1, TNF-a, or HGF, and podoplanin expres-
sion was determined by immunoblotting. Of all the factors
tested, only EGF markedly upregulated podoplanin expression
in MCF7 cells (Figure S5D), while a somewhat weaker induction
could be observed with FGF2 and TGFb (data not shown).
Taken together, the results from these in vitro experiments
confirm that the promigratory and proinvasive effect of podopla-
nin is independent of EMT or a cadherin switch, and is rather due266to a dramatic reorganization of the actin cytoskeleton. In podo-
planin-transfected cells, the loss of stress fibers is accompanied
by the formation of microspikes and filopodia, indicating highly
motile cell membranes. As a consequence, these cells exhibit
enhanced spreading on extracellular matrix components and
increased migratory and invasive capabilities. Thereby, the
induction of podoplanin in the invading tumor front may be
mediated by stromal growth factors, such as EGF, FGF2, and
TGFb.
Podoplanin downregulates RhoA activity but acts
independently of Cdc42
Our results indicate that podoplanin prevents stress fiber forma-
tion. Disruption of stress fibers can also be caused by an inacti-
vation of the small GTPase RhoA pathway (Izawa et al., 1998). To
test whether RhoA inactivation may be involved in the podopla-
nin-mediated reduction of stress fiber formation, we transfected
control and podoplanin-expressing MCF7 cells with constitu-
tive-active or dominant-negative forms of RhoA (Figure 7A). In
addition, we also treated MCF7 cells with Y27632, an inhibitor
of the Rho signaling effector, RhoA-associated kinase (Rock).
Expression of constitutive-active RhoA efficiently reversed the
loss of stress fibers in podoplanin-transfected cells (p < 0.0001,
one-way ANOVA with Newman-Keuls post-test). Dominant-
negative RhoA and the Rock inhibitor Y27632, on the other
hand, repressed stress fiber formation in control cells to levels
observed in podoplanin-expressing cells. To investigate whether
podoplanin-mediated loss of stress fibers was due to an inacti-
vation of RhoA, we performed RhoA activity assays. These ex-
periments revealed a strong downregulation of activated RhoACANCER CELL APRIL 2006
A R T I C L EFigure 6. Podoplanin induces spreading, migra-
tion, and invasion of MCF7 cells
A and B: Podoplanin-transfected cells showed
a markedly accelerated spreading on fibronec-
tin (p < 0.0001, Fisher0s exact test, for all time
points). In addition, more filopodia were detect-
able in podoplanin cells after 90 min of incuba-
tion (compare upper and bottom panel in A).
C: The number of migrating MCF7 cells through 8
mm pore transwell filters is significantly increased
with the expression of podoplanin (*p = 0.0072,
two-sided t test).
D: Podoplanin expression also significantly in-
duces invasion of MCF7 cells through a matri-
gel-coated transwell filter (*p = 0.0019, two-sided
t test).
Data are representative of four (B) or three (C
and D) independent experiments, respectively,
and are shown as mean 6 SEM.in podoplanin-transfected cells as compared to control cells
(Figure 7C).
In contrast to stress fiber formation by RhoA, the Rho family
GTPase Cdc42 and Rac1 are known to induce filopodia and la-
mellipodia, respectively (Fukata et al., 2003; Sahai and Marshall,
2002). To investigate the mechanisms of filopodia formation in
podoplanin-transfected MCF7 cells, we transfected these cells
with either constitutive-active Cdc42 or dominant-negative
Cdc42. In dominant-negative Cdc42-transfected cells, podopla-
nin still mediated the formation of filopodia, although a modest
reduction in filopodia formation was observed in both podopla-
nin-expressing and MCF7-control cells (Figure 7B). Conversely,
constitutive-active Cdc42 dramatically increased filopodia for-
mation in both cell types. Interestingly, the Rock inhibitor
Y27632 also induced filopodia formation in MCF7 control cells
(Figure 7B and Figure S7). To verify these results, we performed
Cdc42 activity assays, which revealed a significant reduction in
Cdc42 activities between podoplanin-transfected and control
cells (Figure 7C). Activity assays for Rac1, the third member of
the Rho familiy of small GTPases, also showed a downregulation
of Rac1 activity upon podoplanin expression (Figure 7C). Yet,
transfection of MCF7 and MCF7 podoplanin cells with constitu-
tive-active and dominant-negative Rac1 did not result in a signif-
icant change in cell morphology (data not shown). Together,
these results suggest that podoplanin-mediated formation of
filopodia does not involve the activation of Cdc42 or Rac1.
Rather, inhibition of RhoA or Rock activities directly caused the
formation of filopodia.
To investigate the functional impact of RhoA downregulation
on cell invasion, MCF7 cells stably transfected with constitu-
tive-active RhoA or dominant-negative RhoA or treated with
Y27632 were analyzed in a matrigel invasion assay (Figure 7D).
Stable expression of constitutive-active RhoA inhibited invasion
of control MCF7 cells. Conversely, MCF7 cells transfected with
dominant-negative RhoA or treated with Y27632 exhibitedCANCER CELL APRIL 2006markedly increased cell invasion (Figure 7D and Figure S7).
These results support the notion that podoplanin induces tumor
cell invasion by inhibiting the RhoA pathway. Treatment of both
control and podoplanin-transfected MCF7 cells with tissue in-
hibitor of MMPs (TIMP2), a general MMP inhibitor, almost com-
pletely abrogated cellular invasion (Figure 7D).
These results indicate that podoplanin downregulates RhoA
activity, thereby ablating stress fibers, inducing filopodia forma-
tion, and promoting tumor cell migration and invasion. Thereby,
the enhanced invasion properties of podoplanin-expressing
cells appear to depend on the activity of MMPs.
Coexpression of podoplanin and E-cadherin
in the invasive front of human cancer
To investigate whether podoplanin possesses an invasion-
inducing function in human cancers, histological sections of
squamous cell carcinomas (from esophagus, skin, larynx, cervix,
and lung) and adenocarcinomas (from lobular breast cancer,
prostate, and colon) were stained with antibodies against podo-
planin (red) and E-cadherin (brown) (Figure 8). A total of 189 tu-
mor fronts were analyzed. Approximately 80% of the investi-
gated tissue samples of human squamous cell cancers of the
lung, skin, esophagus, larynx, and cervix expressed podoplanin.
Notably, in all these samples, podoplanin expression was re-
stricted to the outer cell layer of the invading tumor fronts (Fig-
ures 8A–8E). Similar to podoplanin-expressing b tumor cells
and MCF7 cells, podoplanin and E-cadherin were coexpressed
in the invasive front of squamous cell carcinomas (Figures 8A–
8E). In contrast to squamous cell carcinomas, adenocarcinomas
did not express podoplanin in their invading fronts, although E-
cadherin expression was partially maintained in the tumor tissue
samples analyzed. The notable exception was lobular breast
cancer, which coexpressed podoplanin together with E-
cadherin in areas of the invading front (Figure 8F). The results of
the analysis of human cancer biopsies suggest an important267
A R T I C L EFigure 7. Podoplanin downregulates RhoA,
Cdc42, and Rac activity
A: Expression of podoplanin represses stress fiber
formation in MCF7 cells. Expression of dominant-
negative RhoA (dn-RhoA) abrogates stress fiber
formation in control-transfected cells, indicating
that RhoA activity is required for stress fiber forma-
tion in MCF7 cells. Expression of constitutive-
active RhoA (ca-RhoA) increases the number of
stress fibers in both control and podoplanin-trans-
fected cells. The Rock inhibitor Y27632 inhibits the
formation of stress fibers in MCF7 cells.
B:Podoplanin induces filopodia formation. Trans-
fection of constitutive-active Cdc42 (ca-Cdc42)
in control- and podoplanin-transfected cells re-
sults in a strong increase in the number of filopo-
dia. Transfection of dominant-negative Cdc42
(dn-Cdc42) in podoplanin-transfected cells
does not significantly affect filopodia formation,
whereas the Rock inhibitor Y27632 induces filopo-
dia formation in MCF7 control cells.
C: Analysis of RhoA, Cdc42, and Rac1 GTPase
activity by GST-C21 and GST-PAK pulldown
assays, respectively. Note that podoplanin
expression strongly reduces RhoA, Cdc42, and
Rac1 activities.
D: Invasion of MCF7 cells is promoted if cells are
transfected with podoplanin or dominant-nega-
tive RhoA or are treated with the Rock inhibitor
Y27632. Invasion of MCF7 cells is reduced if cells
are transfected with constitutive-active RhoA.
Upon treatment with TIMP2, invasion is markedly
reduced in both podoplanin-expressing and
control MCF7 cells.
Data are shown as mean 6 standard deviation.role for podoplanin in the progression of squamous cell carcino-
mas and possibly of specific adenocarcinomas. Apparently,
human squamous cell carcinomas reveal a phenotype of large in-
vading tumor fronts without microinvasion, which corresponds to
the phenotype of collective cell migration (Friedl and Wolf, 2003).
Together, the experimental results from human cancer biop-
sies, cultured MCF7 breast cancer cells, and the Rip1Tag2
mouse model of carcinogenesis indicate that upregulated
expression of podoplanin is causing tumor cell invasion by
a pathway that is independent of EMT or the ablation of E-cad-
herin function. It most likely acts via specific changes in RhoA
signaling, in the organization of ERM proteins, and the actin
cytoskeleton, and, as a result, mediates collective cell migration
in cancers with conelike invasion patterns.
Discussion
Recently, it has been reported that podoplanin expression is
upregulated in different human cancers, suggesting a role for
podoplanin in tumor progression (Schacht et al., 2005). Here,
we employed a transgenic mouse model of carcinogenesis, cul-
tured human breast cancer cells, and biopsies from cancer268patients to investigate the functional contribution of podoplanin
to tumor progression. Transgenic expression of podoplanin in
Rip1Tag2 transgenic mice caused an acceleration of tumor
progression with a higher incidence of tumor invasion and tumor
malignancy, without the formation of lymph node or distant
organ metastasis.
The presence of podoplanin during tumor progression in
Rip1Tag2 mice had a rather unexpected impact on cell adhesion
molecules in b tumor cells. Notably, expression of the epithelial
adherens junction protein E-cadherin and its cytoplasmic linker
molecules b catenin and p120 catenin and the tight junction pro-
tein ZO-1 was maintained during the progression from a benign
tumor (adenoma) to an invasive tumor (carcinoma) in double-
transgenic Rip1Podo;Rip1Tag2 mice. In addition, we could not
detect any upregulation of N-cadherin or any other mesenchy-
mal marker in the invasive tumors of double-transgenic mice.
This is surprising, since the loss of E-cadherin has been shown
to be a rate-limiting step in the transition from adenoma to carci-
noma in Rip1Tag2 single-transgenic mice (Perl et al., 1998).
Apparently, podoplanin is able to induce tumor cell invasion
without the need for a cadherin switch or epithelial-mesenchy-
mal transition (EMT).CANCER CELL APRIL 2006
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chemical analysis of squamous cell cancers of the lung, skin,
esophagus, larynx, and cervix of cancer patients revealed ex-
pression of podoplanin in the invading tumor front in the pres-
ence of E-cadherin. In addition, podoplanin was also expressed
in human lobular breast cancer. Notably, podoplanin was found
to be exclusively expressed in the outer cell layer of the invasive
tumor front, whereas E-cadherin was found in both the podopla-
nin-expressing cancer cells and the inner cells of the invasive
tumor front. This particular localization of podoplanin expression
raises the question of whether factors secreted from stromal
cells can induce podoplanin expression. Indeed, we found that
EGF, FGF2, and TGFb can upregulate expression of podoplanin
in MCF7 cells, raising the possibility that stroma-derived growth
factors may induce the specific expression of podoplanin in the
invading tumor front.
Together, the results demonstrate that overexpression of
podoplanin (1) induces filopodia formation and cell polarization,
(2) enhances b1-integrin mediated cell spreading and adhesion
on extracellular matrix, (3) leads to increased cell invasion which
is dependent on the action of MMPs, and (4) increases cell migra-
tion. These processes resemble the steps necessary for collec-
tive cell migration as recently described (Friedl et al., 2004; Friedl
and Wolf, 2003). In the case of collective cell migration, epithelial
markers, E-cadherin-mediated cell-cell adhesion, andb integrin-
mediated cell-matrix adhesion are maintained, while EMT does
Figure 8. Podoplanin and E-cadherin are coexpressed in the invasive front
of human cancers
Immunohistochemical staining for podoplanin (red) and E-cadherin
(brown) reveals high expression of both molecules in the invading front of
(A) invasive human esophageal carcinoma, (B) human skin squamous cell
cacinoma, (C) human larynx carcinoma, (D) human cervix carcinoma, (E)
human lung squamous cell carcinoma, and (F) human lobular breast can-
cer. Whereas E-cadherin is expressed in all carcinoma cells, podoplanin is
detectable exclusively in the outer cell layer of the invading front. Inserts:
103 higher magnification of the panel showing coexpression of E-cadherin
(brown) and podoplanin (red) in cells of the invasive tumor front (arrows).
Scale bar = 50 mm.CANCER CELL APRIL 2006not occur. Many human cancers, including most squamous
cell carcinomas and a few adenocarcinomas, exhibit such a his-
tological phenotype of collective cell migration. Here, we have
shown that E-cadherin is coexpressed with podoplanin in the
invasive front of most human squamous cell carcinomas. Such
organization of an invading sheet of cells is not only present in
the mouse model and the human cancer biopsies, but is also
observed in podoplanin-expressing MCF7 cells: while the cells
seem to adhere by their rear ends via E-cadherin-mediated
adhesion to their next neighbor, they display filopodia on their
invading fronts. This observation is also consistent with the
fact that podoplanin-expressing MCF7 cells migrate as a front
and not as single cells in scratch wounding assays (Figure S6).
Thereby, the cells exhibit polarized migration, as determined
by the reorientation of the Golgi apparatus (data not shown).
Taken together, these results strongly suggest that podoplanin
mediates a novel molecular pathway of collective cell migration.
This mechanism stands in contrast to the invasion of single dis-
seminating tumor cells, a process that in most cases involves
a cadherin switch and EMT. While the latter process certainly
promotes metastasis formation, the contribution of podopla-
nin-mediated collective cell migration to the metastatic process
remains to be determined.
A first analysis of the signaling events that may underlie podo-
planin-induced tumor invasion reveals that the activity of the
small GTPase RhoA is reduced in podoplanin-expressing cells,
which also lack stress fibers. Conversely, stress fibers of podo-
planin-transfected cells could be reconstituted by the expres-
sion of a constitutive-active from of RhoA, suggesting that podo-
planin is acting upstream of RhoA. Unexpectedly, the activity of
Cdc42, which is known to play an important role in filopodia for-
mation, is not upregulated by podoplanin. Moreover, the expres-
sion of a dominant-negative form of Cdc42 does not significantly
repress podoplanin-induced filopodia formation, suggesting
a pathway that induces filopodia independently of Cdc42 ac-
tivity. Podoplanin-mediated downregulation of Rho activity is
sufficient to induce filopodia formation and increased cell migra-
tion: inhibition of Rho activity by the expression of a dominant-
negative form of RhoA or by an inhibitor of the RhoA effector
kinase Rock promotes filopodia formation. Rac activity is also
downregulated in podoplanin transfected cells, but seems to
be without functional relevance for the cellular parameters
analyzed in MCF7 cells.
Here, we report a distinct function for podoplanin, the induc-
tion of collective cell migration and invasion in the absence of
EMT. One major molecular change detected upon podoplanin
expression is the combined inactivation of all three major Rho
family GTPases, RhoA, Rac1, and Cdc42, a constellation that
thus far has not been reported in any specific cellular context.
We can only speculate on the molecular mechanisms by which
podoplanin modulates such repression and how the loss of
RhoA activity actually leads to filopodia formation and cell migra-
tion and invasion. Podoplanin is highly glycosylated on its extra-
cellular domain, and the intracellular terminus consists of only
nine amino acids. Moreover, there is no apparent homology to
any other protein domains and, hence, podoplanin may act by
novel molecular pathways involving as yet unknown binding
partners, including soluble ligands or cell surface molecules
interacting with podoplanin’s carbohydrate moiety or signaling
effector molecules at the inside of the cell. However, immunopre-
cipitation experiments did not reveal any direct binding partner269
A R T I C L Eof podoplanin. The significant colocalization of ezrin and podo-
planin in filopodia-like structures together with increased phos-
phorylation of ezrin in podoplanin-expressing cells suggest
that ERM proteins may play a major role in podoplanin’s modu-
lation of the actin cytoskeleton. The Rho family of small GTPases
exerts multiple effects on the phosphorylation of ERM proteins:
RhoA and Cdc42 are thought to promote, and Rac to inhibit,
ERM protein phosporylation (Ivetic and Ridley, 2004, Matsui
et al., 1998). However, in our experiments, the activities of all
three Rho GTPases are found to be downregulated, whereas
ezrin is highly phosphorylated. Hence, whether the increased
phosphorylation of ezrin and other ERM proteins is due to an
overall repression of Rho GTPase activities or involves a hitherto
unknown pathway, mediated by podoplanin, remains to be
elucidated.
Database expression analyses did not identify any established
carcinoma cell line that expressed significant amounts of podo-
planin, thus excluding siRNA knockdown experiments which
would be important in further investigating podoplanin’s tumor
invasive function. Moreover, since podoplanin knockout mice
are not viable (Schacht et al., 2003), conditional knockout ap-
proaches will have to be employed to ablate podoplanin function
in mouse models of tumorigenesis in vivo.
In conclusion, we hypothesize that podoplanin induces collec-
tive tumor cell invasion in the absence of a cadherin switch or
EMT. Unraveling the molecular details of this process and iden-
tifying the signaling molecules and pathways involved in it may
have a major impact on cancer diagnosis and therapy and,
thus, deserve future research.
Experimental procedures
Transgenic mice
Rip1Podo transgenic mice were generated according to standard proce-
dures (Labosky et al., 1994). The entire coding region of mouse podoplanin
was amplified by RT-PCR using the primer pair 50-gcaattctagaatgtggaccgtgc
cag-3 and 50-gcaataagcttttagggcgagaaccttc-3 and mouse kidney cDNA as
template and cloned under the control of the rat insulin gene II promoter
(Rip1; Hanahan, 1985). The genotypes of six founder mice were confirmed
by Southern blot and PCR analysis. Transgene expression was confirmed
by RT-PCR and immunohistochemical and immunoblotting analysis. One po-
doplanin-expressing mouse line, with approximately 23 inserted transgene
copies, was used for further experimentation. Generation and phenotypic
characterization of Rip1Tag2 mice has been described previously (Hanahan,
1985). Rip1Podo female mice were crossed with Rip1Tag2 male mice to gen-
erate double-transgenic Rip1Podo;Rip1Tag2 mice. Mice were kept in a strict
C57Bl/6 background. PCR primers were: Rip1Podo: 50-CTGCAGCTTCA
GCCCCTCTG-30 and 50-CTGGCACGGTCCACATTCTAG-30; Rip1Tag2: 50-
GGACAAACCACAACTAGAATGGCAG-30 and 50-CAGAGCAGAATTGTGGA
GTGG-30.
All experiments performed with mice were in accordance with the guide-
lines of the Swiss Federal Veterinary Office (SFVO) and the regulations of
the Cantonal Veterinary Office of Basel-Stadt.
Histopathological analysis
Mice were sacrificed at 12 weeks of age. Tumor number and diameter were
measured, and tumor volumes were calculated assuming a spherical shape
of the tumors. The preparation of paraffin and frozen tissue sections and im-
munohistochemical and immunofluorescent analysis was performed as de-
scribed previously (Perl et al., 1998). The following primary antibodies were
used at the dilutions indicated: hamster anti-mouse podoplanin, 1:500 (8.1.1,
DSHB, Iowa University); rabbit anti-human podoplanin, 1:100 (Breiteneder-
Geleff et al., 1999); rat anti-E-cadherin, 1:100 (Zymed, San Diego, California);
mouse anti-N-cadherin, 1:100 (Zymed, San Diego, California); rabbit anti-
b catenin, 1:150 (Sigma, St. Louis, Missouri); mouse anti-p120 catenin,2701:150 (Transduction Laboratories, San Jose, California); rat anti-CD31,
1:100 (BD Biosciences, San Jose, California); mouse anti-moesin, 1:100
(BD Biosciences, San Jose, California); mouse anti-ezrin, 1:100 (BD Biosci-
ences, San Jose, California); rabbit anti-phospho-ezrin/radixin/moesin
(Chemicon, Dietkon, Switzerland); rat anti-ZO-1, 1:100 (Chemicon, Teme-
cula, California); goat anti-insulin, 1:50 (Dako, Baar, Switzerland); rabbit
anti-glucagon, 1:50 (Linco, St. Charles, USA); Alexa fluor 488 phalloidin,
1:50 (Molecular Probes, San Diego, California). In case of mouse anti-mouse
antibodies, background was reduced by additional blocking with the m.o.m.
kit (Vector Laboratories, Burlingame, California). Staining was evaluated on an
AxioVert and a LSM 510 META confocal microscope (Zeiss, Oberkochen,
Germany). Histological staging and grading was done in a blindfold manner
and repeated twice.
MCF7 cell transfection and induction experiment
A cDNA fragment encoding human podoplanin was subcloned into pIRES
(Clontech, Mountain View, California). Constitutive-active and dominant-neg-
ative Cdc42, RhoA, and Rac1 cloned in pTriEx-4 (Kinexus, Vancouver, Can-
ada) were a generous gift from O. Pertz (The Scripps Research Institute, La
Jolla, California). Vectors and empty vector controls were transfected into
MCF7 cells using the Amaxa electroporation system following the manufac-
turer’s instructions (Amaxa, Ko¨ln, Germany). Cells were selected in 750 mg/
ml G418. Transient transfections of MCF7 cells were performed with Fugene
(Roche, Basel, Switzerland). Cells grown on a coverslip were fixed in 4% para-
formaldehyde for 15 min, incubated with 0.2% Triton-X for 2 min, washed in
PBS, blocked with 5% goat serum for 15 min, and stained with the appropriate
primary and secondary antibodies as described above.
Immunoblotting
For total cell lysates, cells were lysed at 4ºC in RIPA-plus buffer (50 mM Tris-
Hcl [pH 8], 150 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 0.5% NaDoc, 10% glyc-
erol, 1% NP40, 0.1% SDS, 1 mM NaF, 2 mM NaVO4, 0.1 mM PMSF, 1 mM
DTT, and protease inhibitor cocktail). 30 mg of cleared protein lysates were
separated by SDS-PAGE and electroblotted on PDVF membranes, and
proteins were visualized with the appropriate primary and secondary anti-
bodies and ECL (Amersham, Otelfingen, Switzerland) on superRX films
(Fuji, Dielsdorf, Switzerland).
Migration and invasion assays
Cell migration was determined by using a modified two-chamber migration
assay (Falcon BD, Franklin Lakes, New Jersey) with a pore size of 8 mm. For
the invasion assay, the membrane was coated with 20 ml of a 2.5 mg/ml solu-
tion of matrigel (Falcon BD). For both assays, 105 MCF7 cells were seeded in
1% fetal calf serum/DMEM medium (Sigma, St. Louis, Missouri) in the upper
chamber, and the lower chamber was filled with 10% fetal calf serum/DMEM
medium. After 24 hr incubation at 37ºC, cells in the upper chamber were care-
fully removed with a cotton swab and the cells that had traversed the mem-
brane were fixed in 4% paraformaldehyde/HBS-Ca2+, stained with crystal
violet (0.5% in 20% methanol), and counted. For functional assays, the
Rock inhibitor Y27632 (Sigma Aldrich, Basel) and the tissue inhibitor of matrix
metalloproteases 2 (TIMP2, a kind gift of A. Noel, Liege, Belgium) were added
to the cell suspensions at a concentration of 10 mM and 200 nM, respectively.
Cell spreading assay
To determine cell spreading on fibronectin, 24-well plates were coated with 15
mg/ml fibronectin (Sigma, St. Louis, Missouri). 104 cells were then plated in low
serum medium (1% FCS in DMEM), and 30 min after seeding, the medium was
changed to eliminate unattached cells. Cells were incubated at 37ºC and
monitored in regular intervals. Adherent cells were photographed under
phase contrast and counted as flattened or round cells. Cell spreading was
confirmed in four independent experiments.
RhoA, Cdc42, and Rac activity assay
The RhoA, Cdc42, and Rac activity assays were performed as described
(Sander et al., 1999). Briefly, 53106 cells were lysed before incubation with
GST-PAK (for Cdc42 and Rac) or GST-C21 fusion protein (for RhoA). After
precipitation, complexes were washed with lysis buffer, resolved by SDS-
PAGE, immunoblotted, and analyzed with antibodies against RhoA, Cdc42,
and Rac (Transduction Laboratories, San Jose, California).CANCER CELL APRIL 2006
A R T I C L EStatistical analysis
Statistical analysis and graphs were performed with GraphPad Prism soft-
ware (GraphPad Software Inc., San Diego, USA). Fisher’s exact test was
used for the binomial analysis of the adenoma and carcinoma frequency,
E-cadherin presence or absence in carcinomas, and flattened or round cells
in the cell spreading assay. The chi-square test was employed to statistically
analyze carcinoma gradings. Statistical analysis of the incidence of MCF7 cell
filopodia as well as the quantification of MCF7 cell migration and invasion was
done by unpaired, two-sided t test. Normality testing was performed using the
Kolmogorov-Smirnov test with Dallal-Wilkinson-Lilliefor p value.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
seven supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/9/4/261/DC1/.
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